Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy

Leukemia

Volumn 13, Issue 2, 1999, Pages 289-294

  Puthier, D ^a   Pellat Deceunynck, C ^a   Barille S ^a   Robillard, N ^a   Rapp, M J ^b   Juge Morineau, N ^b   Harousseau, J L ^b   Bataille, R ^a   Amiot, M ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b Dept d'Hématologie ^*  (France)

Author keywords

Apoptosis; Bcl 2; Multiple myeloma; Plasma cells; Proliferation; Reactive plasmacytosis

Indexed keywords

PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; ASCITES; BONE MARROW; BONE MARROW CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PATHOGENESIS; PLASMA CELL; PLASMACYTOMA; PLASMACYTOSIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033031281     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401302     Document Type: Article

References (26)

1. White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996; 10: 1-15.
2. Yang E, Korsmeyer S. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 1996; 88; 386-401.
3. Reed JC. Cytochrome C: can't live with it - can't live without it. Cell 1997; 91: 559-562.
4. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 1996; 183: 2219-2226.
5. Borner C. Diminished cell proliferation associated with the death protective activity of Bcl-2. J Biol Chem 1996; 271: 12695-12698.
6. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996; 13: 1511-1519.
7. O'Keilly LA, Huang DCS, Strasser A. The cell death inhibitor Bcl-2 and Its homologues influence control of cell cycle entry. EMBO J 1996; 15: 6979-6990.
8. Huang D, O'Reilly L, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997; 16: 4628-4638.
9. Liu Y, Mason D, Johnson G, Abbot S, Gregory C, Hardie D, Gordon J, Maclennan I. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol 1991; 21: 1905-1910.
10. Hamilton M, Barker H, Ball J, Drew M, Abbot S, Franklin I. Normal and neoplastic human plasma cells express bcl-2 antigen. Leukemia 1991; 5: 768-771.
11. Pettersson M, Jernberg-Wiklund H, Larsson L, Sundström C, Givo I. Tsujimoto Y, Nilsson K. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992; 79: 495-502
12. Jourdan M, Ferlan M, Legouffe E, Horvathova M, Liautard J, Rossi JF, Widjenes J, Klein B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998; 100: 637-646.
13. Carayon P, Bord A. Identification of DNA-replicating lymphocytes subsets using a new method to label the bromo-deoxyurudine incorporated into the DNA. J Immunol Meth 1992; 147: 225-230.
14. Pellat-Deceunynck C, Bataille R, Robillard N, Harrousseau J-L, Rapp M-J, Juge-Morineau N, Widjenes J, Amiot M. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84: 2597-2603.
15. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma - new biological insights and advances therapy. Blood 1989; 73: 865-879.
16. Hallek M, Bergsagel L, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
17. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8: 363-372.
18. O'Reilly L, Harris A, Tarlinton D, Corcoran L, Strasser A. Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. J Immunol 1997; 159: 2301-2311.
19. Drewinko R, Alexanian H, Boyer B, Barlogie B, Rubinow S. The growth fraction of human myeloma cells. Blood 1981; 57: 333-338.
20. Jourdan M, Bataille R, Seguin J, Xg Z, Chaptal P, Klein B. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthris Rheum 1990; 33: 398-402.
21. Ogata A, Chauchan D, Teoh G, Treon S, Urashima M, Schlossman R, Anderson K. IL-6 triggers myeloma cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212-2221.
22. Wang H, Rapp U, Reed J. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638.
23. Winter J, Anderson J, Reed JC, Krajewski S, Variakojis D, Bauer KD, Fisher RI, Gordon LI, Oken MM, Jiang S, Jeffries D, Domer P. Bcl-2 expression correlates with lower proliferative activity in the intermediate-and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southern Oncology Group Cooperative Laboratory Study. Blood 1998; 91: 1391-1398.
24. Lipponen P, Pietilainen T, Kosma V, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein Bcl-2 is expressed in well-differentiated breast carcinoma with favourable prognosis. J Pathol 1995; 177: 49-55.
25. Pezzela F, Turley H, Kuzu I, Tungekar M, Dunnill M, Pierce C, Harris A, Gatter KC, Masson DY. Bcl-2 protein in non-small-cell lung carcinoma. New Engl J Med 1993; 329: 690-694.
26. Ong F, Nieuwkoop JV, Grool-Swings GD, Hermans J, Harvey M, Kluin P, Kluin-Nelemans J. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 1995; 9: 1282-1284.